Biogen | BIIB - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
AbbVie USD 1.77B 608K 2026-06
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
ALKERMES USD 168.03M 489K 2026-09
Amgen USD 541M 0 2026-09
Bayer EUR 982.42M 0 2026-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
Incyte USD 200.98M 1.03M 2026-06
Merck USD 2.47B 1.05M 2026-06
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novartis USD 1.89B 12.09M 2026-09
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 83.33M 445K 2026-06
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sanofi EUR 1.2B 0 2026-09
Sanofi EUR 1.2B 2.15M 2026-06
Sarepta Therapeutics USD 105.62M 53K 2026-06
Teva Pharmaceutical Industries USD 1.17B 2M 2026-09
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
United Therapeutics USD 42.68M 521K 2026-06
Vertex Pharmaceuticals USD 253.5M 200K 2026-09